UBS Maintains Neutral on Moderna, Raises Price Target to $150

Benzinga Newsdesk www.benzinga.com Positive 55.1%

Neg 0% Neu 0% Pos 55.1%

UBS analyst Michael Yee maintains Moderna (NASDAQ:MRNA) with a Neutral and raises the price target from $50 to $150.

Comments

No comments yet. Be the first!